Long-term results of rituximab–intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy

Abstract

Rituximab-IVIg combination treatment seems to be effective and safe for treating patients with EBA resistant to conventional treatments.